Myasthenia Gravis Disease Market Research Report 2019: By Diagnosis (Imaging, Blood Tests, Electrodiagnostic, Edrophonium Test), Treatment (Medication, Surgery, HSCT), End-User (Hospitals, Clinics, Academic Research Institutes) – Global Forecast Till 2023
Myasthenia Gravis Disease Market Outlook
Myasthenia gravis is a neuromuscular disorder that leads to the weakening of skeletal muscles, which are responsible for the movement of the body. This condition occurs due to the impairment of communication between muscles and nerve cells.
global market for the myasthenia gravis disease is expected to grow at a CAGR of approximately 7.5% during 2017 to 2023.
Get Free Sample Research copy at https://www.marketresearchfuture.com/sample_request/5843
Industry Segmentation
The global myasthenia gravis disease market has been segmented on the basis of diagnosis, treatment, and end-user.
- On the basis of diagnosis, the global myasthenia gravis disease market can be segmented into imaging, blood tests, electrodiagnostic, edrophonium test, pulmonary function test, and others. The imaging segment is classified into X-ray, Computed Tomography (CT), Magnetic Resonance Imaging (MRI), and others.
- On the basis of treatment, the global myasthenia gravis disease market can be segmented into medication, surgery, autologous Hematopoietic Stem Cell Transplantation (HSCT), plasmapheresis and intravenous immunoglobulin, and others.
- On the basis of medication segment is divided into acetylcholinesterase inhibitors, immunosuppressant drugs, steroids, and others. The acetylcholinesterase inhibitors are classified into atropine, neostigmine, pyridostigmine, and others. The immunosuppressant drugs are further divided into prednisone, azathioprine, mycophenolate mofetil, tacrolimus, and rituximab. The steroids are further divided into prednisone and others. The surgery is finally divided into thymectomy and others.
- On the basis of end-user, the global myasthenia gravis disease market is segmented into hospitals, clinics, academic research institutes, and others.
Competitive Analysis by Major Key Players
Some of the key players in the global myasthenia gravis disease market are Valeant Pharmaceuticals International (U.S.), Sun Pharmaceuticals Industries Ltd. (India), Piramal Healthcare (India), Novartis Pharmaceuticals Corporation (Switzerland), Apotex Corporation (Canada), Teva Pharmaceutical Industries Ltd. (Israel), RPG Life Sciences (India), Cipla (India), F. Hoffmann Roche La Ltd. (Switzerland), Bristol-Myers Squibb Company (U.S.), Biogen Inc. (U.S.), and AbbVie Inc. (U.S.), GlaxoSmithKline plc (UK), Fresenius Kabi (Germany), and others.
Brows complete Premium Research Report at https://www.marketresearchfuture.com/reports/myasthenia-gravis-disease-market-5843
As per a study conducted by the Myasthenia Gravis Foundation of America, myasthenia gravis is the most common type of neuromuscular disorder.
Comprehensive Regional Analysis
The global myasthenia gravis disease market consists of regions, namely, the Americas, Europe, Asia Pacific, and the Middle East and Africa.
The Americas dominates the global myasthenia gravis disease market owing to the growing prevalence of muscular dystrophies such as congenital muscular dystrophies, distal muscular dystrophy, Becker muscular dystrophies, and others along with the extensive demand for diagnostic and treatment services. Moreover, major companies are launching FDA approved drugs thus increasing the commercial access to these drugs worldwide.
The European region is the second largest market for the global myasthenia gravis disease owing to the adoption of new therapies, skilled medical professionals, and availability of advanced treatment facilities. According to the National Institute of Neurological Disorders and Stroke (NINDS), an estimated 15 cases of myasthenia gravis occurs per 100,000 people in the United Kingdom every year.
The Asia Pacific market is the fastest growing therapeutic market owing to the large aging population in countries such as Japan and China coupled with the rising awareness about the long-term effects of muscular dystrophies. Moreover, the cumulative initiatives of the World Health Organization (WHO) in countries such as Japan, China, and India are likely to foster the strengthening of major Asian countries in the future. The Middle East and Africa is likely to exhibit steady growth in this market due to the demand for drugs in remote areas and increasing prevalence of neurological diseases.
Avail Discount at https://www.marketresearchfuture.com/check-discount/5843
This impairment causes difficulties in the contraction and relaxation of muscles which are crucial for carrying out daily activities, resulting in muscle weakness. It mostly affects the muscles that control the eyes and eyelids, facial expressions, chewing, and speaking.
About Market Research Future: MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.
Contact:
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar, Pune
+1 646 845 9312
